Mink Therapeutics Inc (INKT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $11.89 (+1.54%), Market cap $0.05B, 52-week low–high $6.89 ~ $64.17.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with an
Financial statements, price targets, institutional (13F) holdings and related news for Mink Therapeutics Inc are updated in real time on BlackAll Trade.
Mink Therapeutics Inc trades at $11.89 (+1.54%). Real-time quotes and charts are available on BlackAll Trade.
Mink Therapeutics Inc has a market cap of about $0.05B.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural kille